4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) CEO David Kirn sold 92,001 shares of the company’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $27.13, for a total value of $2,495,987.13. Following the completion of the transaction, the chief executive officer now directly owns 1,059,153 shares in the company, valued at approximately $28,734,820.89. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
David Kirn also recently made the following trade(s):
- On Tuesday, January 23rd, David Kirn sold 5,696 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $18.41, for a total value of $104,863.36.
- On Thursday, January 4th, David Kirn sold 40,732 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $20.31, for a total value of $827,266.92.
4D Molecular Therapeutics Stock Performance
Shares of 4D Molecular Therapeutics stock traded down $0.78 on Monday, hitting $27.85. The stock had a trading volume of 1,930,662 shares, compared to its average volume of 1,591,509. The firm has a market capitalization of $1.19 billion, a P/E ratio of -10.20 and a beta of 2.63. 4D Molecular Therapeutics, Inc. has a twelve month low of $9.44 and a twelve month high of $35.61. The stock has a 50 day moving average of $19.40 and a 200 day moving average of $15.74.
Hedge Funds Weigh In On 4D Molecular Therapeutics
Several hedge funds have recently made changes to their positions in the business. Bfsg LLC bought a new stake in 4D Molecular Therapeutics in the 4th quarter worth about $30,000. International Assets Investment Management LLC bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at approximately $36,000. US Bancorp DE increased its stake in 4D Molecular Therapeutics by 580.7% in the fourth quarter. US Bancorp DE now owns 1,797 shares of the company’s stock worth $36,000 after purchasing an additional 1,533 shares during the period. Lazard Asset Management LLC lifted its holdings in 4D Molecular Therapeutics by 44.2% during the 2nd quarter. Lazard Asset Management LLC now owns 2,190 shares of the company’s stock valued at $38,000 after buying an additional 671 shares in the last quarter. Finally, Ensign Peak Advisors Inc increased its position in 4D Molecular Therapeutics by 167.9% during the 3rd quarter. Ensign Peak Advisors Inc now owns 7,180 shares of the company’s stock valued at $58,000 after purchasing an additional 4,500 shares during the period.
Analysts Set New Price Targets
Several research firms recently weighed in on FDMT. Leerink Partnrs raised 4D Molecular Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Wednesday, October 18th. BMO Capital Markets raised their price target on shares of 4D Molecular Therapeutics from $50.00 to $70.00 and gave the stock an “outperform” rating in a research report on Monday, February 5th. SVB Leerink upgraded shares of 4D Molecular Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 price target on the stock in a research note on Wednesday, October 18th. Cantor Fitzgerald initiated coverage on shares of 4D Molecular Therapeutics in a research note on Tuesday, October 24th. They set an “overweight” rating and a $32.00 target price for the company. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $81.00 price objective on shares of 4D Molecular Therapeutics in a research note on Wednesday, February 7th. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $39.44.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy.
- Five stocks we like better than 4D Molecular Therapeutics
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 attractive stocks that insiders are buying
- Quiet Period Expirations Explained
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- How to Evaluate a Stock Before Buying
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.